Clinical Trials · NCT00241020

Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma

CompletedPhase 3Octreotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novartis Pharmaceuticals
Enrollment
270
Start date
Jun 2002
Locations
See registry
Primary endpoint
Overall Survival
View Octreotide compound reference